Abstract
A 62-year-old woman treated with fluvastatin experienced three separate thrombocytopenic illnesses, severe on two occasions associated with nadir platelet count of 57 000/µL and 75 000/µL. The hospital pharmacist replaced fluvastatin by pravastatin during three stays. Platelet count has increased some days after this substitution. These results suggest that fluvastatin could be involved in these thrombocytopenic episodes.
© 2015 Société Française de Pharmacologie et de Thérapeutique.
MeSH terms
-
Acetaminophen / administration & dosage
-
Acetaminophen / therapeutic use
-
Binding, Competitive
-
Comorbidity
-
Cytochrome P-450 CYP2C9 / metabolism
-
Cytochrome P-450 CYP2C9 Inhibitors / pharmacokinetics
-
Drug Substitution
-
Drug Synergism
-
Fatty Acids, Monounsaturated / administration & dosage
-
Fatty Acids, Monounsaturated / adverse effects*
-
Fatty Acids, Monounsaturated / pharmacokinetics
-
Fatty Acids, Monounsaturated / therapeutic use
-
Female
-
Fluvastatin
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Inactivation, Metabolic / drug effects
-
Indoles / administration & dosage
-
Indoles / adverse effects*
-
Indoles / pharmacokinetics
-
Indoles / therapeutic use
-
Middle Aged
-
Pravastatin / therapeutic use
-
Recurrence
-
Thrombocytopenia / chemically induced*
-
Valproic Acid / administration & dosage
-
Valproic Acid / adverse effects
-
Valproic Acid / pharmacokinetics
-
Valproic Acid / therapeutic use
Substances
-
Cytochrome P-450 CYP2C9 Inhibitors
-
Fatty Acids, Monounsaturated
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Indoles
-
Acetaminophen
-
Fluvastatin
-
Valproic Acid
-
CYP2C9 protein, human
-
Cytochrome P-450 CYP2C9
-
Pravastatin